QT interval prolongation in liver cirrhosis: Innocent bystander or serious threat?

Expert Review of Gastroenterology and Hepatology

Volumn 6, Issue 1, 2012, Pages 57-66

  Bernardi, Mauro ^a   Maggioli, Caterina ^a   Dibra, Valmir ^a   Zaccherini, Giacomo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

blockers; gastrointestinal bleeding; liver cirrhosis; liver transplantation; long QT syndrome; portal hypertension; QT interval; sympathetic nervous system

Indexed keywords

AMIODARONE; ARSENIC TRIOXIDE; BEPRIDIL; CARDIOTOXIN; CHLORPROMAZINE; CIPROFLOXACIN; CISAPRIDE; CLARITHROMYCIN; DISOPYRAMIDE; DOFETILIDE; DOMPERIDONE; DROPERIDOL; ERYTHROMYCIN; HALOPERIDOL; IBUTILIDE; LIDOFLAZINE; MESORIDAZINE; METHADONE; MOXIFLOXACIN; NADOLOL; NORFLOXACIN; PIMOZIDE; PROCAINAMIDE; QUINIDINE; SOTALOL; SPARFLOXACIN; THIORIDAZINE; VERAPAMIL;

ADRENERGIC SYSTEM; BACTERIAL INFECTION; CAUSE OF DEATH; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFECT; ELECTROCARDIOGRAM; HEART ATRIUM FIBRILLATION; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; INFECTION COMPLICATION; LIVER CIRRHOSIS; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; PORTAL HYPERTENSION; PROGNOSIS; QT PROLONGATION; REVIEW; TORSADE DES POINTES;

ACTION POTENTIALS; ARRHYTHMIAS, CARDIAC; ELECTROCARDIOGRAPHY; HUMANS; LIVER CIRRHOSIS;

EID: 83455224187     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.11.86     Document Type: Review

References (67)

1. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennecs cirrhosis. J. Clin. Invest. 32, 1025-1033 (1953)
2. Wong F. Cirrhotic cardiomyopathy. Hepatol. Int. 3, 294-304 (2009)
3. Zambruni A, Trevisani F, Caraceni P, Bernardi M. Cardiac electrophysiological abnormalities in patients with cirrhosis. J. Hepatol. 44, 994-1002 (2006)
4. Rudy Y. Molecular basis of cardiac action potential repolarization. Ann. NY Acad. Sci. 1123, 113-118 (2008)
5. Malik M, Farbom P, Batchvarov V, Hnatkova K, Camm AJ. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 87, 220-228 (2002)
6. Malik M. The imprecision in heart rate correction may lead to artificial observations of drug induced QT interval changes. Pacing Clin. Electrophysiol. 25, 209-216 (2002)
7. Zambruni A, Di Micoli A, Lubisco A, Domenicali M, Trevisani F, Bernardi M. QT interval correction in patients with cirrhosis. J. Cardiovasc. Electrophysiol. 18, 77-82 (2007)
8. Mangoni AA, Kinirons MT, Swift CG, Jackson SH. Impact of age on QT interval and QT dispersion in healthy subjects: a regression analysis. Age Ageing 32, 326-331 (2003)
9. Stramba-Badiale M, Locati EH, Martinelli A, Courville J, Schwartz PJ. Gender and the relationship between ventricular repolarization and cardiac cycle length during 24-h Holter recordings. Eur. Heart J. 18, 1000-1006 (1997)
10. Khan IA. Long QT syndrome: diagnosis and management. Am. Heart J. 143, 7-14 (2002)
11. Roden DM. Drug-induced prolongation of the QT interval. N. Engl. J. Med. 350, 1013-1022 (2004)
12. Khan IA. Clinical and therapeutic aspects of congenital and acquired long QT syndrome. Am. J. Med. 112, 58-66 (2002)
13. Roden DM. Long QT syndrome. N. Engl. J. Med. 358, 169-176 (2008)
14. Wang Q. Curran ME, Splawskin I, et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat. Genet. 12, 17-23 (1996)
15. Vyas H, Hejlik J, Ackerman MJ. Epinephrine QT stress testing in the evaluation of congenital long QT syndrome: diagnostic accuracy of the paradoxical QT response. Circulation 113, 1385-1392 (2006)
16. Li EC, Esterly JS, Pohl S, Scott SD, McBride BF. Drug-induced QT-interval prolongation: considerations for clinicians. Pharmacotherapy 30, 684-701 (2010)
17. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81, 299-307 (1995)
18. Zhang S, Zhou Z, Gong Q, Makielski JC, January CT. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ. Res. 84, 989-998 (1999)
19. Day CP, James OF, Butler TJ, Campbell RW. QT prolongation and sudden cardiac death in patients with alcoholic liver disease. Lancet 341, 1423-1428 (1993)
20. Bernardi M, Calandra S, Colantoni A, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 27, 28-34 (1998)
21. Puthumana L, Chaudhry V, Thuluvath PJ. Prolonged QTc interval and its relationship to autonomic cardiovascular reflexes in patients with cirrhosis. J. Hepatol. 35, 733-738 (2001)
22. Bal JS, Thuluvath PJ. Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplantation. Liver Int. 23, 243-248 (2003)
23. Genovesi S, Prata Pizzala DM, Pozzi M, et al. QT interval prolongation and decreased heart rate variability in cirrhotic patients: relevance of hepatic venous pressure gradient and serum calcium. Clin. Sci. (Lond.) 116, 851-859 (2009)
24. Adigun AQ, Pinto AG, Flockhart DA, et al. Effect of cirrhosis and liver transplantation on the gender difference in QT interval. Am. J. Cardiol. 95, 691-694 (2005)
25. Mohamed R, Forsey PR, Davies MK, Neuberger J. Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology 23, 1128-1134 (1996)
26. Henriksen JH, Gøtze JP, Fuglsang S, Christensen E, Bendtsen F, Moller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 52, 1511-1517 (2003)
27. Shin WJ, Kim YK, Song JG, et al. Alterations in QT interval in patients undergoing living donor liver transplantation. Transplant. Proc. 43, 170-173 (2011)
28. Ytting H, Henriksen JH, Fuglsang S, Bendtsen F. Prolonged Q-T(c) interval in mild portal hypertensive cirrhosis. J. Hepatol. 43, 637-644 (2005)
29. Trevisani F, Merli M, Savelli F, et al. QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. J. Hepatol. 38, 461-467 (2003)
30. Møller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 87, 9-15 (2002)
31. Ma Z, Meddings JB, Lee SS. Membrane physical properties determine cardiac beta-adrenergic receptor function in cirrhotic rats. Am. J. Physiol. 267, 87-93 (1994)
32. Alqahtani SA, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Semin. Liver Dis. 28, 59-69 (2008)
33. Ohkubo H, Okuda K, Iida S, Ohnishi K, Ikawa S, Makino I. Role of portal and splenic vein shunts and impaired hepatic extraction in the elevated serum bile acids in liver cirrhosis. Gastroenterology 86, 514-520 (1984)
34. Desai MS, Shabier Z, Taylor M, et al. Hypertrophic cardiomyopathy and dysregulation of cardiac energetics in a mouse model of biliary fibrosis. Hepatology 51, 2097-2107 (2010)
35. Kaser S, Foger B, Waldenberger P, et al. Transjugular intrahepatic portosystemic shunt (TIPS) augments hyperinsulinemia in patients with cirrhosis. J. Hepatol. 33, 902-906 (2000)
36. Zierler K, Wu FS. Insulin acts on Na, K, and Ca currents. Trans. Assoc. Am. Physicians 101, 320-325 (1988)
37. Zhong J, Hwang TC, Adams HR, Rubin LJ. Reduced L-type calcium current in ventricular myocytes from endotoxemic guinea pigs. Am. J. Physiol. 273, H2312-H2324 (1997)
38. Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 18, 1139-1143 (1993)
39. Navasa M, Follo A, Filella X, et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 27, 1227-1232 (1998)
40. Haque R, Kan H, Finkel MS. Effects of cytokines and nitric oxide on myocardial E-C coupling. Basic Res. Cardiol. 93, 86-94 (1998)
41. Hendrickse MT, Triger DR. Peripheral and cardiovascular autonomic impairment in chronic liver disease: prevalence and relation to hepatic function. J. Hepatol. 16, 177-183 (1992)
42. Trevisani F, Sica G, Mainquà P, et al. Autonomic dysfunction and hyperdynamic circulation in cirrhosis with ascites. Hepatology 30, 1387-1392 (1999)
43. Henriksen JH, Bendtsen F, Hansen EF, Moller S. Acute nonselective b-adrenergic blockade reduces prolonged frequency adjusted QT interval in patients with cirrhosis. J. Hepatol. 40, 239-246 (2004)
44. Zambruni A, Trevisani F, Di Micoli A, et al. Effect of chronic b-blockade on QT interval in patients with liver cirrhosis. J. Hepatol. 48, 415-421 (2008)
45. Edvardsson N, Olsson SB. Effects of acute and chronic beta-receptor blockade on ventricular repolarisation in man. Br. Heart J. 45, 628-636 (1981)
46. Kim YK, Hwang GS, Shin WJ, Bang JY, Cho SK, Han SM. Effect of propranolol on the relationship between QT interval and vagal modulation of heart rate variability in cirrhotic patients awaiting liver transplantation. Transplant. Proc. 43, 1654-1659 (2011)
47. Zambruni A, Di Micoli A, Bracci E, et al. Acute gastrointestinal bleeding prolongs QT interval in cirrhosis. J. Hepatol. 48, 125 (2008)
48. Zingarelli B, Squadrito F, Altavilla D, et al. Evidence for a role of nitric oxide in hypovolemic hemorrhagic shock. J. Cardiovasc. Pharmacol. 19, 982-986 (1992)
49. Roumen RM, Hendriks T, van der Ven-Jongekrijg J, et al. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann. Surg. 218, 769-776 (1993)
50. Ward CA, Ma Z, Lee SS, Giles WR. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis. Am. J. Physiol. 273, G537-G544 (1997)
51. Conrath CE, Opthof T. Ventricular repolarization: an overview of (patho) physiology, sympathetic effects and genetic aspects. Prog. Biophys. Mol. Biol. 92, 269-307 (2006)
52. Kass RS, Moss AJ, Long QT syndrome: novel insights into the mechanisms of cardiac arrhythmias. J. Clin. Invest. 112, 810-815 (2003)
53. Kass RS, Wiegers SE. The ionic basis of concentration-related effects of noradrenaline on the action potential of calf cardiac purkinje fibres. J. Physiol. 322, 541-558 (1982)
54. Priori SG, Corr PB. Mechanisms underlying early and delayed after depolarizations induced by catecholamines. Am. J. Physiol. 258, H1796-H1805 (1990)
55. Tan HL, Hou CJ, Lauer MR, Sung RJ. Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann. Intern. Med. 122, 701-714 (1995)
56. Al Sibae MR, Cappell MS. Accuracy of MELD scores in predicting mortality in decompensated cirrhosis from variceal bleeding, hepatorenal syndrome, alcoholic hepatitis, or acute liver failure as well as mortality after non-transplant surgery or TIPS. Dig. Dis. Sci. 56, 977-987 (2011)
57. Hansen S, Møller S, Bendtsen F, Jensen G, Henriksen JH. Diurnal variation and dispersion in QT interval in cirrhosis: relation to haemodynamic changes. J. Hepatol. 47, 373-380 (2007)
58. Sheehan J, Perry IJ, Reilly M, et al. QT dispersion, QT maximum and risk of cardiac death in the Caerphilly Heart Study. Eur. J. Cardiovasc. Prev. Rehabil. 11, 63-68 (2004)
59. Stein LB, Dabezies MA, Silverman M, Brozena FC. Fatal torsade de pointes occurring in a patient receiving intravenous vasopressin and nitroglycerin. J. Clin. Gastroenterol. 15, 171-174 (1992)
60. Faigel DO, Metz DC, Kochman ML. Torsade de pointes complicating the treatment of bleeding esophageal varices: association with neuroleptics, vasopressin, and electrolyte imbalance. Am. J. Gastroenterol. 90, 822-824 (1995)
61. Nakasone H, Sugama R, Sakugawa H, et al. Alcoholic liver cirrhosis complicated with torsade de pointes during plasma exchange and emodiafiltration. J. Gastroenterol. 36, 564-568 (2001)
62. Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int. J. Antimicrob. Agents 29, 374-379 (2007)
63. Urge J, Sincl F, Procházka V, Urbanek K. Terlipressin-induced ventricular arrhythmia. Scand. J. Gastroenterol. 43, 1145-1148 (2008)
64. Di Micoli A, Zambruni A, Bracci E, et al. Torsade de pointes during amiodarone infusion in a cirrhotic woman with a prolonged QT interval. Dig. Liver Dis. 41, 535-538 (2009)
65. Chalasani N, Gorski JC, Patel NH, Hall SD, Galinsky RE. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts. Hepatology 34, 1103-1108 (2001)
66. Vuppalanchi R, Juluri R, Ghabril M, et al. Drug-induced QT prolongation in cirrhotic patients with transjugular intrahepatic portosystemic shunt. J. Clin. Gastroenterol. 45, 638-642 (2011)
67. Garcia-Tsao G. Bacterial infections in cirrhosis: treatment and prophylaxis. J. Hepatol. 42(Suppl. 1) S85-S92 (2005)